Progyny Inc (PGNY)

Receivables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
Revenue (ttm) US$ in thousands 1,167,818 1,140,069 1,135,369 1,111,361 1,091,902 1,036,101 959,749 874,714 787,727 700,482 617,337 551,196 501,082 473,730 450,213 385,920 344,979 309,953 272,210
Receivables US$ in thousands 282,324 340,224 370,296 362,109 286,969 318,166 310,458 362,245 282,967 323,735 266,064 229,420 158,257 159,981 166,367 139,866 92,064 103,302 73,496
Receivables turnover 4.14 3.35 3.07 3.07 3.80 3.26 3.09 2.41 2.78 2.16 2.32 2.40 3.17 2.96 2.71 2.76 3.75 3.00 3.70

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,167,818K ÷ $282,324K
= 4.14

The receivables turnover ratio measures how efficiently a company is able to collect payments from its customers. A higher receivables turnover ratio indicates that the company is able to collect its outstanding receivables more quickly.

Analyzing the receivables turnover of Progyny Inc over the provided periods, we can observe fluctuations in the ratio. In June 2020, the ratio was 3.70, indicating that Progyny collected its receivables approximately 3.70 times during that period. The ratio decreased to 2.32 by June 2022, suggesting a decline in the company's ability to collect payments efficiently. Subsequently, the ratio improved to 4.14 by December 2024, showing a positive trend in collecting receivables.

It is important to note that a declining receivables turnover ratio could signal potential issues with collecting payments from customers promptly, while an increasing ratio may indicate improved collection efficiency. Overall, monitoring the trend of the receivables turnover ratio can provide insights into Progyny's accounts receivable management and liquidity.


Peer comparison

Dec 31, 2024

Company name
Symbol
Receivables turnover
Progyny Inc
PGNY
4.14
DaVita HealthCare Partners Inc
DVA
5.01
Sotera Health Co
SHC
6.65